Rubén Nogueiras

Feb 5, 2024 | nature.com | S. Rasika |Rubén Nogueiras |Markus Schwaninger

Correction to: Nature Reviews Endocrinology https://doi.org/10.1038/s41574-024-00955-3, published online 29 January 2024. In the version of the article initially published, the surname of Markus Schwaninger appeared incorrectly (as Scwaninger) and has now been corrected in the HTML and PDF versions of the article. About this articleRasika, S., Nogueiras, R., Schwaninger, M. et al. Author Correction: Seeing through the fog: a neuroendocrine explanation for post-COVID cognitive deficits.

Jan 29, 2024 | nature.com | S. Rasika |Rubén Nogueiras |Markus Schwaninger

Gonadotropin-releasing hormone is implicated in cognitive functions, and its loss is a factor in pathological brain ageing. There are similarities between these processes and the neurological and cognitive deficits observed in patients with long COVID. Here, we explore the hypothesis that neuroanatomical and transcriptomic alterations associated with long COVID could stem from this neuroendocrine perturbation.

Jun 12, 2023 | nature.com | Rubén Nogueiras |Michael A. Nauck |Matthias H. Tschöp

AbstractThe discovery and development of so-called gut hormone co-agonists as a new class of drugs for the treatment of diabetes and obesity is considered a transformative breakthrough in the field. Combining action profiles of multiple gastrointestinal hormones within a single molecule, these novel therapeutics achieve synergistic metabolic benefits. The first such compound, reported in 2009, was based on balanced co-agonism at glucagon and glucagon-like peptide-1 (GLP-1) receptors.